Biocon Denies API Selloff Rumors As It Completes Biologics Integration
Indian Giant Dismisses Media Reports Of $1.5bn Divestment As ‘Baseless And Speculative’
Biocon has rejected as “baseless and speculative” Indian media reports that it is considering divestment options for its API business. Meanwhile, the firm has celebrated completion of the integration of Viatris’s biosimilars business into its Biocon Biologics subsidiary.
